Featured Research

from universities, journals, and other organizations

Cancer Researchers Describe New Class Of Angiogenesis Proteins

Date:
July 3, 2003
Source:
University Of California - San Diego
Summary:
Researchers at the Rebecca and John Moores UCSD Cancer Center, and colleagues from throughout the state, describe a new class of proteins that not only promotes therapeutic angiogenesis in an entirely new way, but also avoids vascular permeability – a troubling side effect seen with other agents now being tested.

Researchers at the Rebecca and John Moores UCSD Cancer Center, and colleagues from throughout the state, describe a new class of proteins that not only promotes therapeutic angiogenesis in an entirely new way, but also avoids vascular permeability – a troubling side effect seen with other agents now being tested.

Angiogenesis, the process by which the body forms new blood vessels, occurs in cancer, arthritis and other diseases, and in normal processes such as embryonic development, wound healing and ovulation. Researchers worldwide are working on ways to promote angiogenesis in the treatment of some diseases, such as heart disease and peripheral arterial disease (PAD), and to inhibit angiogenesis in others, such as cancer.

The research team, led by Judith Varner, Ph.D., associate adjunct professor of medicine at UCSD School of Medicine, reports its in vitro and animal study findings on the Del-1 protein in the July 1 issue of the Journal of Clinical Investigation.

Del-1, an extracellular matrix (ECM) protein, was discovered about four years ago by co-author Thomas Quertermous, M.D., of Stanford. In this paper the researchers describe its function, the mechanism by which it works, and its potential for human therapy. They have christened this new class of pro-angiogenesis factors "angiomatrix" proteins.

"Most of the pro-angiogenesis proteins we know of so far are growth factors, which are soluble, so they may disappear after a short time, and are often associated with side effects that can limit their clinical potential," said Varner. "Our data show that Del-1 is very stable, doesn't diffuse away, and has the potential ability to continually stimulate angiogenesis."

Varner added that Del-1 does not cause vascular permeability, or edema, a damaging condition in which the cells lining the blood vessels move apart from each other, allowing lymphocytes and other cells to enter tissues and release their oxidants.

In animal studies the researchers compared Del-1 to one of the leading growth factors now being tested – vascular endothelial growth factor (VEGF).

"In our testing in animal models of ischemia, the two agents were similar in their ability to stimulate angiogenesis and improve muscle function, but there were no side effects with the Del-1 therapy, unlike with VEGF," she said.

These same findings have been borne out in a recently completed Phase I clinical trial of Del-1 sponsored by Valentis, Inc. of Burlingame, CA. The company announced June 9 at the 6th Annual Meeting of the American Society of Gene Therapy in Washington, D.C., that its lead product, a Del-1 drug for the treatment of PAD was well tolerated at all doses tested and there were no serious side effects seen. While the Phase I study was designed to test safety, the company reports evidence of dose-related activity. Based on the trial results, Valentis is planning a Phase II trial to begin soon.

Varner has been studying Del-1 since it was discovered. Initially she found that it promoted migration and survival of endothelial cells through an adhesion receptor called alpha-v-beta-3. She knew a piece of the puzzle was missing, however, because that receptor is not expressed on normal blood vessels, only vessels already undergoing angiogenesis.

"We didn't know how Del-1 actually initiated angiogenesis until we found another receptor, the alpha-v-beta-5, that's further upstream in the process," she said. "You absolutely need that receptor to develop angiogenesis in response to the Del-1 protein."

Varner's team found that Del-1 initiates angiogenesis by locking onto the cell membrane using the alpha-v-beta-5 cell adhesion receptor. Once tethered it activates a powerful transcription factor called Hox D3. The transcription factor launches a cascade of events that changes the profile of the cell, making it angiogenic. Later in the process, Del-1 interacts with the alpha-v-beta-3 receptor to promote migration and survival of the endothelial cell.

While this paper explored Del-1's pro-angiogenic role in ischemia, Varner said, she and co-author Quertermous have also studied its expression and function in cancer. Del-1 is expressed and promotes angiogenesis in many tumors. "In the cancer setting, you want to inhibit angiogenesis," she said. "Knowing the mechanism will help us design therapies than can inhibit Del-1."

###

Besides Varner, co-authors are Jingping Zhong, Ph.D., Department of Medicine and Moores UCSD Cancer Center; Brian Eliceiri, Ph.D., and Dwayne Stupack, Ph.D., of the Department of Immunology, The Scripps Research Institute, La Jolla; Kalyani Penta, Ph.D., Gordon Sakamoto, M.D., and Thomas Quertermous, M.D., all of the Donald W. Reynolds Cardiovascular Clinical Research Center, Stanford University; Mike Coleman, Ph.D., of Valentis Inc.; and Nancy Boudreau, Ph.D., of the Surgical Research Laboratories, University of California, San Francisco.


Story Source:

The above story is based on materials provided by University Of California - San Diego. Note: Materials may be edited for content and length.


Cite This Page:

University Of California - San Diego. "Cancer Researchers Describe New Class Of Angiogenesis Proteins." ScienceDaily. ScienceDaily, 3 July 2003. <www.sciencedaily.com/releases/2003/07/030701222333.htm>.
University Of California - San Diego. (2003, July 3). Cancer Researchers Describe New Class Of Angiogenesis Proteins. ScienceDaily. Retrieved April 23, 2014 from www.sciencedaily.com/releases/2003/07/030701222333.htm
University Of California - San Diego. "Cancer Researchers Describe New Class Of Angiogenesis Proteins." ScienceDaily. www.sciencedaily.com/releases/2003/07/030701222333.htm (accessed April 23, 2014).

Share This



More Health & Medicine News

Wednesday, April 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com
How to Master Motherhood With the Best Work/Life Balance

How to Master Motherhood With the Best Work/Life Balance

TheStreet (Apr. 22, 2014) In the U.S., there are more than 11 million couples trying to conceive at any given time. From helping celebrity moms like Bethanny Frankel to ordinary soon-to-be-moms, TV personality and parenting expert, Rosie Pope, gives you the inside scoop on mastering motherhood. London-born entrepreneur Pope is the creative force behind Rosie Pope Maternity and MomPrep. She explains why being an entrepreneur offers the best life balance for her and tips for all types of moms. Video provided by TheStreet
Powered by NewsLook.com
Catching More Than Fish: Ugandan Town Crippled by AIDS

Catching More Than Fish: Ugandan Town Crippled by AIDS

AFP (Apr. 22, 2014) The village of Kasensero on the shores of Lake Victoria was where HIV-AIDS was first discovered in Uganda. Its transient population of fishermen and sex workers means the nationwide programme to combat the virus has had little impact. Duration: 02:30 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins